Home Intro
Our lead program barzolvolimab is a humanized monoclonal antibody inhibitor of KIT, a key receptor tyrosine kinase required for the function and survival of mast cells, which play a central role in the onset and progression of many severe inflammatory, allergic and autoimmune diseases. By targeting a core pathological driver of these diseases, we have designed barzolvolimab with the potential to be a best-in-class treatment option and improve the lives of patients.
